Dutch cultivated meat pioneer Meatable is now poised to ramp up growth plans following its acquisition of a competitor’s lab meat division.
The takeover of Uncommon Bio’s platform has given the business an entirely new way to manufacture cultivated meat using cutting-edge non-GMO RNA-based technologies.
Meatable can now grow GMO and non-GMO meat, smoothing the regulatory process and opening up new markets.
The deal brought intellectual property, expert staff and high-performing cell lines into the fold at Meatable, pushing it to an “unmatched position in the field”, the company said.
Meatable is currently in talks with partners around the world to bring product lines to market. The company has raised around €100m since its launch in 2018.
“This acquisition is more than a strategic step – it sets a new standard for cultivated meat production,” added CEO Jeff Tripician.
“By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale. This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb, and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.”
While Meatable has largely focused on pork and beef, the addition of Uncommon Bio’s technology will accelerate development of chicken, lamb and high-flavour breeds.
Uncommon Bio decided to divest its meat cultivation wing in a move to focus on its primary therapeutic technologies business.
Uncommon CEO Benjamina Bollag said she was “incredibly proud” of the team’s work in advancing cultivated meat science.
She added: “We wanted to find the best home for our technology and it’s exciting to see Meatable carry our work forward and apply it at scale. I look forward to continuing our collaboration and watching their continued success and global impact in the years ahead.”
No comments yet